Primary brain tumors in the elderly.
The incidence of primary brain tumors is highest in elderly patients, and advanced age often is a negative prognostic factor. Nevertheless, large randomized studies in this population are scarce. Elderly patients with primary brain tumors also present unique challenges, such as the presence of multiple comorbidities and polypharmacy, decreased tolerance to chemotherapy, and an increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients with glioblastoma and other gliomas, primary central nervous system lymphomas (PCNSLs), and meningiomas. Selected elderly glioblastoma patients with good performance status may benefit from aggressive treatment with surgical resection, radiotherapy, and possibly chemotherapy. For older patients with PCNSLs, high-dose methotrexate-based chemotherapy should be the mainstay option; whole-brain radiation therapy should be avoided in chemosensitive tumors because of the high risk of irreversible and progressive neurotoxicity. Meningiomas often may be followed up in elderly patients, as they usually are asymptomatic and have a slow growth rate. Treatment for elderly patients with primary brain tumors should be individualized, and age alone should not preclude the use of more aggressive treatments.
Nayak
Lakshmi
L
Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. nayakl@mskcc.org
Iwamoto
Fabio M
FM
D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D003937:Diagnosis, Differential; D006801:Humans; D016896:Treatment Outcome
Int J Radiat Oncol Biol Phys. 1992;23(1):9-17
1572835
J Neurooncol. 1998 Aug;39(1):65-70
9760071
J Neurosurg. 2009 Jan;110(1):156-62
18847342
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92
17967509
Acta Neurochir (Wien). 2003 Jan;145(1):5-10
12545256
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
J Clin Oncol. 2009 Oct 1;27(28):4733-40
19720927
Cancer Res. 2001 Feb 1;61(3):1122-8
11221842
Cancer. 2003 Feb 1;97(3):657-62
12548608
Crit Rev Oncol Hematol. 2006 Dec;60(3):256-66
17027278
Cancer. 1993 Apr 15;71(8):2585-97
8453582
Arch Pathol Lab Med. 2005 May;129(5):624-31
15859633
J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8
10601396
Lancet. 2005 Sep 17-23;366(9490):985-90
16168780
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):100-7
11516858
Cancer. 2009 Aug 15;115(16):3758-66
19484785
Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31
231022
Neuro Oncol. 2009 Apr;11(2):211-5
18757775
Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1
12823874
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33
14734474
J Clin Oncol. 2000 Sep;18(17):3144-50
10963643
Cancer. 2003 May 1;97(9):2262-6
12712481
J Neurooncol. 2007 Nov;85(2):207-11
17896079
J Clin Oncol. 2009 Feb 10;27(5):740-5
19114704
Neuro Oncol. 2010 Feb;12(2):164-72
20150383
Cancer. 2007 Sep 15;110(6):1338-44
17647247
J Neurooncol. 2008 Aug;89(1):97-103
18398569
Cancer. 2002 Oct 1;95(7):1504-10
12237919
J Clin Oncol. 2003 Jul 15;21(14):2726-31
12860951
Neurology. 2009 Apr 7;72(14):1217-22
19349600
Ann Neurol. 2008 Dec;64(6):628-34
19107984
N Engl J Med. 2007 Apr 12;356(15):1527-35
17429084
Cancer. 2004 May 15;100(10):2208-14
15139066
J Neurooncol. 2008 May;88(1):97-103
18250965
J Clin Oncol. 2006 Dec 20;24(36):5711-5
17116938
Neurology. 2009 Dec 15;73(24):2093-8
19907009
J Neurooncol. 2009 Jan;91(1):95-100
18758912
Lancet. 2002 Mar 23;359(9311):1011-8
11937180
Neuro Oncol. 2002 Oct;4(4):278-99
12356358
Neurology. 1997 May;48(5):1459-62
9153494
Neurosurgery. 2005 Nov;57(5):866-72; discussion 866-72
16284557
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):835-9
8040031
J Neurosurg. 1978 Sep;49(3):333-43
355604
Neuroepidemiology. 2009;33(1):17-22
19325245
J Clin Oncol. 2004 May 1;22(9):1583-8
15051755
J Clin Oncol. 2002 Dec 15;20(24):4643-8
12488408
Cancer. 2009 Dec 1;115(23):5534-40
19708033